Adverse effect of adjuvant tamoxifen in premenopausal breast cancer with cyclin D1 gene amplification

Cancer Research

Volumn 65, Issue 17, 2005, Pages 8009-8016

  Jirström, Karin ^a   Stendahl, Maria ^a   Rydén, Lisa ^a   Kronblad, Åsa ^a   Bendahl, Pär Ola ^b   Stål, Olle ^c   Landberg, Göran ^a  

^a LUND UNIVERSITY   (Sweden)

^b LUND UNIVERSITY HOSPITAL   (Sweden)

^c LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN A2; CYCLIN D1; CYCLINE; ESTROGEN RECEPTOR; TAMOXIFEN; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREMENOPAUSE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADULT; AGED; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLIN A; FEMALE; GENE AMPLIFICATION; GENES, BCL-1; HUMANS; MIDDLE AGED; PROGNOSIS; TAMOXIFEN;

EID: 24744449148     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-05-0746     Document Type: Article

References (41)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000;100:57-70.
2. Malumbres M, Barbacid M. To cycle or not to cycle: a critical decision in cancer. Nat Rev Cancer 2001;1:222-31.
3. Keyomarsi K, Pardee AB. Redundant cyclin overexpression and gene amplification in breast cancer cells. Proc Natl Acad Sci U S A 1993;90:1112-6.
4. Gillett C. Amplification and overexpression of cyclin D1 in breast cancer detected by immunohistochemical staining. Cancer Res 1994;54:1812-7.
5. Buckley MF. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2127-33.
6. Ormandy CJ. Cyclin D1, EMS1 and 11q13 amplification in breast cancer. Breast Cancer Res Treat 2003;78:323-35.
7. Zwijsen RM. CDK-independent activation of estrogen receptor by cyclin D1. Cell 1997;88:405-15.
8. Zwijsen RM. Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 1998;12:3488-98.
9. Trowbridge JM, Rogatsky I, Garabedian MJ. Regulation of estrogen receptor transcriptional enhancement by the cyclin A/Cdk2 complex. Proc Natl Acad Sci U S A 1997;94:10132-7.
10. Rogatsky I, Trowbridge JM, Garabedian MJ. Potentiation of human estrogen receptor α transcriptional activation through phosphorylation of serines 104 and 106 by the cyclin A-CDK2 complex. J Biol Chem 1999;274:22296-302.
11. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-67.
12. Michalides R. Tamoxifen resistance by a conformational arrest of the estrogen receptor α after PKA activation in breast cancer. Cancer Cell 2004;5:597-605.
13. Watts CK. Antiestrogen inhibition of cell cycle progression in breast cancer cells in associated with inhibition of cyclin-dependent kinase activity and decreased retinoblastoma protein phosphorylation. Mol Endocrinol 1995;9:1804-13.
14. Musgrove EA. Growth factor, steroid, and steroid antagonist regulation of cyclin gene expression associated with changes in T-47D human breast cancer cell cycle progression. Mol Cell Biol 1993;13:3577-87.
15. Wilcken NR. Inducible overexpression of cyclin D1 in breast cancer cells reverses the growth-inhibitory effects of antiestrogens. Clin Cancer Res 1997;3:849-54.
16. Hodges LC. Tamoxifen functions as a molecular agonist inducing cell cycle-associated genes in breast cancer cells. Mol Cancer Res 2003;1:300-11.
17. Michalides R. Cyclin A is a prognostic indicator in early stage breast cancer with and without tamoxifen treatment. Br J Cancer 2002;86:402-8.
18. Stendahl M. Cyclin D1 overexpression is a negative predictive factor for tamoxifen response in postmenopausal breast cancer patients. Br J Cancer 2004;90:1942-8.
19. Michalides R. A clinicopathological study on overexpression of cyclin D1 and of p53 in a series of 248 patients with operable breast cancer. Br J Cancer 1996;73:728-34.
20. Swedish Breast Cancer Cooperative Group. Randomized trial of two versus five years of adjuvant tamoxifen for postmenopausal early stage breast cancer. J Natl Cancer Inst 1996;88:1543-9.
21. Stal O. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol 2000;11:1545-50.
22. De Placido S. Twenty-year results of the Naples GUN randomized trial: predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res 2003;9:1039-46.
23. Ryden L. Two years of adjuvant tamoxifen in premenopausal patients with breast cancer: a randomised, controlled trial with long-term follow-up. Eur J Cancer 2005;41:256-64.
24. Bukholm IR, Bukholm G, Nesland JM. Over-expression of cyclin A is highly associated with early relapse and reduced survival in patients with primary breast carcinomas. Int J Cancer 2001;93:283-7.
25. Schraml P. Cyclin E overexpression and amplification in human tumors. J Pathol 2003;200:375-82.
26. Rummukainen JK. Amplification of c-myc by fluorescence in situ hybridization in a population-based breast cancer tissue array. Mod Pathol 2001;14:1030-5.
27. Al-Kuraya K. Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 2004;64:8534-40.
28. Peters G. Chromosome 11q13 markers and D-type cyclins in breast cancer. Breast Cancer Res Treat 1995;33:125-35.
29. Schuuring E. The involvement of the chromosome 11q13 region in human malignancies: cyclin D1 and EMS1 are two new candidate oncogenes. A review. Gene 1995;159:83-96.
30. Hui R. EMS1 amplification can occur independently of CCND1 or INT-2 amplification at 11q13 and may identify different phenotypes in primary breast cancer. Oncogene 1997;15:1617-23.
31. Bekri S. Detailed map of a region commonly amplified at 11q13→q14 in human breast carcinoma. Cytogenet Cell Genet 1997;79:125-31.
32. Courjal F. Mapping of DNA amplifications at 15 chromosomal localizations in 1875 breast tumors: definition of phenotypic groups. Cancer Res 1997;57:4360-7.
33. Berns EM. Oncogene amplification and prognosis in breast cancer: relationship with systemic treatment. Gene 1995;159:11-8.
34. Karlseder J. Patterns of DNA amplification at band q13 of chromosome 11 in human breast cancer. Genes Chromosomes Cancer 1994;9:42-8.
35. Fantl V. Gene amplification on chromosome band 11q13 and oestrogen receptor status in breast cancer. Eur J Cancer 1990;26:423-9.
36. Dickson C. Amplification of chromosome band 11q13 and a role for cyclin D1 in human breast cancer. Cancer Lett 1995;90:43-50.
37. Brookes S. Amplified region of chromosome band 11q13 in breast and squamous cell carcinomas encompasses three CpG islands telomeric of FGF3, including the expressed gene EMS1. Genes Chromosomes Cancer 1993;6:222-31.
38. Schuuring E. The product of the EMS1 gene, amplified and overexpressed in human carcinomas, is homologous to a v-src substrate and is located in cell-substratum contact sites. Mol Cell Biol 1993;13:2891-8.
39. Hui R. EMS1 gene expression in primary breast cancer: relationship to cyclin D1 and oestrogen receptor expression and patient survival. Oncogene 1998;17:1053-9.
40. Paik S. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 2004;351:2817-26.
41. Ma XJ. A two-gene expression ratio predicts clinical outcome in breast cancer patients treated with tamoxifen. Cancer Cell 2004;5:607-16.